Switch theme
Sign up to access all valuation multiples
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
2017
552
LTM Revenue $155M
LTM EBITDA -$299M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Idorsia has a last 12-month revenue (LTM) of $155M and a last 12-month EBITDA of -$299M.
In the most recent fiscal year, Idorsia achieved revenue of $135M and an EBITDA of -$271M.
Idorsia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Idorsia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $155M | XXX | $135M | XXX | XXX | XXX |
| Gross Profit | $147M | XXX | $92.0M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | -$299M | XXX | -$271M | XXX | XXX | XXX |
| EBITDA Margin | -192% | XXX | -200% | XXX | XXX | XXX |
| EBIT | -$290M | XXX | -$405M | XXX | XXX | XXX |
| EBIT Margin | -187% | XXX | -300% | XXX | XXX | XXX |
| Net Profit | -$290M | XXX | -$317M | XXX | XXX | XXX |
| Net Margin | -187% | XXX | -234% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Idorsia's stock price is CHF 2 (or $2).
Idorsia has current market cap of CHF 335M (or $402M), and EV of CHF 1.5B (or $1.8B).
See Idorsia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $402M | XXX | XXX | XXX | XXX | $-1.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Idorsia has market cap of $402M and EV of $1.8B.
Idorsia's trades at 13.5x EV/Revenue multiple, and -6.8x EV/EBITDA.
Equity research analysts estimate Idorsia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Idorsia has a P/E ratio of -1.4x.
See valuation multiples for Idorsia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $402M | XXX | $402M | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 11.8x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBITDA | -6.1x | XXX | -6.8x | XXX | XXX | XXX |
| EV/EBIT | -6.3x | XXX | -4.5x | XXX | XXX | XXX |
| EV/Gross Profit | 12.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | -5.4x | XXX | -3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIdorsia's last 12 month revenue growth is 60%
Idorsia's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Idorsia's rule of 40 is -107% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Idorsia's rule of X is -42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Idorsia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA Margin | -192% | XXX | -200% | XXX | XXX | XXX |
| EBITDA Growth | -56% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -107% | XXX | -140% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 128% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 368% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Idorsia acquired XXX companies to date.
Last acquisition by Idorsia was XXXXXXXX, XXXXX XXXXX XXXXXX . Idorsia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Idorsia founded? | Idorsia was founded in 2017. |
| Where is Idorsia headquartered? | Idorsia is headquartered in Switzerland. |
| How many employees does Idorsia have? | As of today, Idorsia has 552 employees. |
| Who is the CEO of Idorsia? | Idorsia's CEO is Mr. Jean-Paul Clozel. |
| Is Idorsia publicy listed? | Yes, Idorsia is a public company listed on SWX. |
| What is the stock symbol of Idorsia? | Idorsia trades under IDIA ticker. |
| When did Idorsia go public? | Idorsia went public in 2017. |
| Who are competitors of Idorsia? | Similar companies to Idorsia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Idorsia? | Idorsia's current market cap is $402M |
| What is the current revenue of Idorsia? | Idorsia's last 12 months revenue is $155M. |
| What is the current revenue growth of Idorsia? | Idorsia revenue growth (NTM/LTM) is 60%. |
| What is the current EV/Revenue multiple of Idorsia? | Current revenue multiple of Idorsia is 11.8x. |
| Is Idorsia profitable? | Yes, Idorsia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Idorsia? | Idorsia's last 12 months EBITDA is -$299M. |
| What is Idorsia's EBITDA margin? | Idorsia's last 12 months EBITDA margin is -192%. |
| What is the current EV/EBITDA multiple of Idorsia? | Current EBITDA multiple of Idorsia is -6.1x. |
| What is the current FCF of Idorsia? | Idorsia's last 12 months FCF is -$342M. |
| What is Idorsia's FCF margin? | Idorsia's last 12 months FCF margin is -220%. |
| What is the current EV/FCF multiple of Idorsia? | Current FCF multiple of Idorsia is -5.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
